Arthroscopy Association of Canada Position Statement on Intra-articular Injections for Knee Osteoarthritis

Kopka, Michaela; Sheehan, Brendan; Degen, Ryan M.; Wong, Ivan; Hiemstra, Laurie A.; Ayeni, Olufemi R.; Getgood, Alan; Beavis, Cole; Volesky, Monika; Outerbridge, Ross; Matache, Bogdan A.

doi:10.1177/2325967119860110

Cited by 11 publications

(8 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, use for knee OA remains somewhat controversial. PRP is not supported in the treatment of knee OA by the most recent clinical practice guidelines from the AAOS 15 or the AAC 16 , but more recent meta-analyses and randomized clinical trials are reporting encouraging results with comparable improvements in outcome measures and better durability when compared with HA 7,9 . As a result of these encouraging results, there has been a significant increase in utilization for knee OA.…”

Section: Platelet-rich Plasma and Stem Cellsmentioning

confidence: 99%

Arthroscopy Association of Canada Position Statement on Intra-articular Injections for Hip Osteoarthritis

Degen

Hiemstra²,

Lobo³

et al. 2022

Orthopaedic Journal of Sports Medicine

Self Cite

View full text Add to dashboard Cite

Section: Platelet-rich Plasma and Stem Cellsmentioning

confidence: 99%

Arthroscopy Association of Canada Position Statement on Intra-articular Injections for Hip Osteoarthritis

Degen

Hiemstra²,

Lobo³

et al. 2022

Orthopaedic Journal of Sports Medicine

Self Cite

View full text Add to dashboard Cite

“…The Arthroscopy Association of Canada also issued a position statement on intra-articular injections for knee osteoarthritis in 2019, as follows. 25…”

Section: Autologous Mesenchymal Stem Cellmentioning

confidence: 99%

Therapies for osteoarthritis today and tomorrow: Review

Skrepnik¹

2020

Scripta Medica

View full text Add to dashboard Cite

Osteoarthritis is a common human disease with well understood pathophysiology, signs and symptoms, prevalence, risk factors, pain, and suffering with great understanding of personal, economic and social effects around the world. There are no drugs or treatments considered "disease modifying", with symptomatic control aiming to stave off the final solution of total joint replacement. Regenerative medicine and use of mesenchymal stem cells (MSC) promised hope to change that but have so far fallen short. This review focuses on current knowledge and use of MSC in clinic, completed research, and future directions for development of this once so promising biological treatment. Powerful treatment for pain in form of monoclonal antibodies against Nerve Growth Factor (NGF) are getting close to FDA approval in the US. Wnt signaling pathway modulators that decrease inflammation, increase function and potential to regenerate cartilage should be presented to the FDA early next year.

show abstract

“…[ 17 – 21 ] Currently, PRP treatment is still recommended against in patients with knee OA in several guidelines because of the heterogeneity of the evidence as well as lack of standardization in the PRP preparation method and composition. [ 4 , 22 ] Therefore, results of animal studies which promoting the development of treatment approaches for human diseases are used to inform human research. [ 23 ] A number of animal experiments have been carried out to study the effect of PRP on the progression of osteoarthritis.…”

Section: Introductionmentioning

confidence: 99%

Effects of platelet-rich plasma injection for pain control and cartilage repair in knee osteoarthritis

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: Knee osteoarthritis (KOA) is a common disabling condition and a heavy financial burden to the society. Platelet-rich plasma (PRP) is considered to be an effective method in the repair and regeneration of cartilage and alleviate pain in KOA. But the utilising of PRP to treat KOA in clinical has shown variable results from many studies. The objective of this protocol is to determine the efficacy of PRP in pain control and cartilage repair in KOA animal models. Method: We will search the following three electronic databases: MEDLINE, EMBASE and Web of Science. The primary outcome will include the histological score of cartilage and pain score. The secondary outcomes will be the behavioural assessments and cartilage thickness. SYRCLE's risk of bias tool will be used to assessment the risk of bias of including studies. The standardized mean difference and 95% confidence interval will be used to calculate the effect of PRP treatment. The I2 inconsistency values will be used to calculated the heterogeneity between studies. Results: The results of this paper will be submitted to a peer-reviewed journal for publication. Conclusion: This research will determine the efficacy of PRP of the treatment of knee osteoarthritis model. PROSPERO registration number: CRD42020181589.

show abstract

Arthroscopy Association of Canada Position Statement on Intra-articular Injections for Knee Osteoarthritis

Cited by 11 publications

References 55 publications

Arthroscopy Association of Canada Position Statement on Intra-articular Injections for Hip Osteoarthritis

Arthroscopy Association of Canada Position Statement on Intra-articular Injections for Hip Osteoarthritis

Therapies for osteoarthritis today and tomorrow: Review

Effects of platelet-rich plasma injection for pain control and cartilage repair in knee osteoarthritis

Contact Info

Product

Resources

About